Myasthenia gravis: Frequently asked questions
John A. Morren, Yuebing Li
Abstract
Myasthenia gravis is a disorder of neuromuscular junction transmission, the result of antibodies against the post-synaptic aspect of the neuromuscular junction. Its clinical hallmark is fatigable weakness of skeletal muscles, which tends to vary in location and severity among patients. It is treated with pyridostigmine, immunotherapy, and thymectomy. Treatment is often individualized according to disease severity, antibody status, comorbidities, and other factors. This review uses a question-and-answer format to provide up-to-date, high-yield, clinically relevant information on myasthenia gravis.
Topics & Concepts
Myasthenia gravisMedicineThymectomyPyridostigmineNeuromuscular junctionWeaknessNeuromuscular transmissionClinical trialNeurologyMuscle weaknessNeuromuscular diseaseDiseaseInternal medicineSurgeryNeurosciencePsychiatryBiologyMyasthenia Gravis and ThymomaPeripheral Neuropathies and DisordersParkinson's Disease and Spinal Disorders